Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Subscribe To Our Newsletter & Stay Updated